The post 1Globe Health Institute appeared first on MassBio.

ABC’s production facility is segmented into separate cell culture suites and purification suites, supported by a common production infrastructure.

Together with rigorously developed quality systems (changeover, change control, etc.), this enables ABC to operate as a campaign based facility, with multiple products safely manufactured at the same time in different areas and at different times in the same area. Extensive and validated equipment covering the full range of biopharmaceutical unit operations combine with state-of-the art control systems to enable a broad range of biopharm processes. ABC manufactures both for Abbott and for other companies on a contract manufacturing basis.

In drug discovery research, ABC’s mission is to discover new small molecule and biologic therapies for immunological diseases. We are working toward the discovery of anti-inflammatory compounds that alter signal transduction in immune cells and antibodies that target autoimmune

mechanisms. In collaboration with scientists from Abbott discovery

centers we are also developing novel multi-functional Biologics as optimized therapeutic solutions for the treatment of cancer, pain and neurological disorders, Our research group includes highly trained scientists in the disciplines of molecular and cellular biology, pharmacology, medicinal chemistry and biotechnology.

ABC offers prospective employees a complete benefits package including generous paid vacation; matching 401(k) plan, pension plan, tuition reimbursement, medical, dental and life insurance benefits and health and dependent care reimbursement accounts. We are an equal opportunity employer.

ABC is the perfect place to bring your biopharmaceutical career or product.

The post Abbott Laboratories appeared first on MassBio.

At AbbVie, we have the expertise of a proven pharmaceutical leader and the focus and passion of an entrepreneur and innovator. The result is something rare in health care today – a global biopharmaceutical company that has the ability to discover and advance innovative therapies and meet the health needs of people and societies around the globe.

The post AbbVie appeared first on MassBio.

Bringing disciplines together in a cross-functional environment, this team includes antibody engineers, molecular biologists, and cell biologists who are driving innovative solutions to bring new treatments to patients faster.

Learn more about the work being done at AbCellera’s locations in Boston, USA; Vancouver, Canada; Sydney, Australia; and Cambridge, UK by visiting abcellera.com

The post AbCellera appeared first on MassBio.

The post Acadia Pharmaceuticals appeared first on MassBio.

The post Acceleron Pharma, Inc. appeared first on MassBio.

Extreme flexibility in design due to limitless diversity of structure and associated characteristics
Ease of analysis, aiding feedback in the development process
Dosing simplicity (oral dosing is commonplace for small molecule drugs)
Ease and cost-efficiency of manufacturing

While to date there have been relatively few inhibitors of RMPs reported, analogs for related protein families have already been described. These include small molecule inhibitors with favorable pharmacological properties, consistent with acceptable safety profiles, good oral bioavailability and pharmacokinetic characteristics that allow for convenient dosing schedules. Accent is undertaking the systematic chemical biology and drug discovery efforts required to characterize and target compelling RNA modifications as new approaches to precision cancer therapeutics.

The Accent team is uniquely qualified to practice SMD discovery and development in the area of RMP inhibitors, building on a track record of success in delivering novel SMDs to the clinic. Among the executive team, scientific advisory board and board of directors, the Accent team has previously delivered more than 200 SMDs to the clinic and, collectively, have contributed to more than 40 approved drugs that are in clinical use today.

At Accent, we are combining cutting-edge approaches to target identification with a robust chemical biology platform and more traditional drug discovery approaches. This approach allows us to identify and prioritize the most critical RMP targets for specific human cancer indications and to swiftly match these targets with novel small molecule inhibitors that serve as powerful starting points for our drug optimization efforts. In partnership with trusted contract research organizations, we are building a model that encourages a diversity of approaches and can respond quickly to identified opportunities.

The post Accent Therapeutics, Inc. appeared first on MassBio.

For more information, visit www.acertx.com

The post Acer Therapeutics Inc. appeared first on MassBio.